News Innoviva, Inc.

Equities

INVA

US45781M1018

Real-time Estimate Cboe BZX Other stock markets 10:52:02 2024-04-26 am EDT			5-day change	1st Jan Change
15.07 ^USD	+0.53%		+1.10%	-5.77%

Apr. 24	Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	CI
Mar. 04	Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	Apr. 25	AQ
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	Apr. 24	BU
Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	Apr. 24	CI
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	Mar. 04	MT
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	Feb. 29	CI
Innoviva: Q4 Earnings Snapshot	Feb. 29	AQ
Earnings Flash (INVA) INNOVIVA Reports Q4 Revenue $85.8M	Feb. 29	MT
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress	Feb. 29	BU
Innoviva, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics	Feb. 06	CI
Innoviva Specialty Therapeutics Appoints David Altarac, MD, as Chief Medical Officer	Feb. 06	AQ
Innoviva Insider Sold Shares Worth $153,810, According to a Recent SEC Filing	Nov. 17	MT
Innoviva Specialty Therapeutics - Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea	Nov. 02	AQ
Innoviva: Q3 Earnings Snapshot	Nov. 01	AQ
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	Nov. 01	CI
Innoviva, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress	Nov. 01	BU
Earnings Flash (INVA) INNOVIVA Posts Q3 Revenue $67.3M	Nov. 01	MT
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea	Nov. 01	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Innoviva, Inc.

Equities

INVA

US45781M1018

Summary

Filters